Phase 3Active, not recruitingAge-related condition

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy

Sponsor
Astellas Pharma Global Development, Inc. (Industry)
Enrollment
982 enrolled
Conditions
Hot Flashes
Interventions
Fezolinetant; Placebo; Tamoxifen; Aromatase inhibitor
Ages
adults, older adults
Registry
NCT06440967, CTIS2024-510719-31-00

Full record on ClinicalTrials.gov

From the registry

One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but cannot be given to women on hormone therapy for breast cancer. Fezolinetant, an alternative to HRT, treats hot flashes for women in menopause. As hot flashes happen in the same way for women on hormone therapy for breast cancer, fezolinetant could help these women. In this study, women on hormone therapy for breast cancer who have moderate to severe hot flashes will take part. They will either take fezolinetant or a placebo to treat their hot flashes. The placebo looks like fezolinetant but doesn't have any medicine in it. The main aim of this study is to confirm if women who take fezolinetant have fewer hot flashes that are less severe compared to women who take the placebo. Women 18 years or older seeking treatment for hot flashes. They can take part in the study if they have an average of 7 or more moderate to severe hot flashes each day. They are having…

Primary outcomes

  • Mean change from Baseline to Week 4 in the frequency of moderate to severe VMS
  • Mean change from Baseline to Week 12 in the frequency of moderate to severe VMS
  • Mean change from Baseline to Week 4 in the severity of moderate to severe VMS
  • Mean change from Baseline to Week 12 in the severity of moderate to severe VMS

History

  1. Study completion expected

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered